Expression of HDAC1 and CBP/p300 in human colorectal carcinomas
- 24 August 2007
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 60 (11) , 1205-1210
- https://doi.org/10.1136/jcp.2005.029165
Abstract
Background: The histone-modifying enzymes histone deacetylase (HDAC) and histone acetyltransferase (HAT) control gene transcriptional activation and repression in human malignancies.Aims: To analyse the expression of HDAC/HAT-associated molecules such as HDAC1, CREB-binding protein (CBP) and p300 in human colorectal carcinomas, and investigate the relationship between their expression levels and clinicopathological parameters.Methods: Expression levels of HDAC1, CBP, and p300 in human colorectal cancer were investigated by immunohistochemistry. In situ hybridisation (ISH) and reverse transcription (RT)-PCR analyses were also carried out to confirm mRNA expression levels of these genes. Immunoreactivity was evaluated semi-quantitatively using a staining index (SI). The relationships between the SIs and clinicopathological findings were analysed and survival curves were calculated using the Kaplan–Meier method and log-rank tests.Results: The mean SIs for HDAC1, CBP, and p300 in this series of tumours were much higher than those in normal colonic mucosa. The presence ofHDAC1andCBPmRNAs on colorectal carcinoma cells as well as normal epithelial cells was confirmed by ISH analysis. A marked increase inp300mRNA levels was detected in a majority of cases by RT-PCR. Among the patients with colorectal cancer, overexpression of p300 (SI>11.9) correlated with a poor prognosis, whereas high CBP expression levels (SI>16.6) indicated long-term survival.Conclusion: Results showed the up-regulation of these three histone-modifying molecules in this series of colorectal cancers and suggested that monitoring of CBP and p300 may assist prediction of the prognosis in patients with colorectal adenocarcinoma.Keywords
This publication has 41 references indexed in Scilit:
- Histone deacetylase inhibitors as new cancer drugsCurrent Opinion in Oncology, 2001
- Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndromeHuman Molecular Genetics, 2001
- Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genesNature Medicine, 2001
- Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.2001
- Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cellsBlood, 2000
- Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell linesInternational Journal of Cancer, 2000
- Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.2000
- Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylationProceedings of the National Academy of Sciences, 2000
- The language of covalent histone modificationsNature, 2000
- Butyrate production from dietary fibre and protection against large bowel cancer in a rat model.Gut, 1993